Janssen collaborated with Apple to check if a new iPhone app can reduce the risk of stroke
Janssen Pharmaceutical companies of Johnson and Johnson and Apple collaborated to offer U.S. adults of 65 years and more to enrol in Heartline study. The study is intended to check whether Heartline Study app on iPhone, and the ECG app and irregular rhythm notification can reduce the risk of stroke and detect atrial fibrillation in the early stages.
Atrial fibrillation is a common form irregular heart rhythm. In a statement, Janssen said that atrial fibrillation is a leading cause of death, however people do not experience symptoms. Thirty-three million people across the world are suffering from atrial fibrillation.
The eligibility criteria of the study are:
· People 65 years and older
· Resident of the United States
· Have original Medicare
· Have iPhone 6S or later models
· People have to agree to provide Medicare claims data
The study includes two groups: one group to use only the Heartline study and the other group use Heartline study, plus ECD rhythm and irregular rhythm notification feature.
The study will be conducted for three years, two years of active engagement and one year of follow up.
The intention of the study is to reduce the time and cost of the clinical trials.